The U.S. Food and Drug Administration (FDA) has granted approval for Merilog, a new rapid-acting insulin biosimilar, offering an advancement in the treatment of diabetes.
Modeled after the widely used Novolog insulin, Merilog is designed to help reduce blood sugar levels in individuals with diabetes, providing healthcare providers and patients with a new option to manage the condition.
Merilog has been classified as a “biosimilar” to Novolog, meaning it is highly similar to the original product with no clinically meaningful differences in safety or effectiveness.
Biosimilars are designed to perform in the same way as their reference products, delivering the same therapeutic benefits.
The approval comes at a time when the demand for cost-effective diabetes treatments continues to grow.
Diabetes, a chronic condition affecting millions worldwide, requires rigorous blood sugar management to prevent complications.
Fast-acting insulins like Merilog are essential for controlling blood sugar spikes, particularly around meal times.
